ASX Share rice
Fri 07 Aug 2020 - 07:22:am (Sydney)

HYD Share Price

HYDRIX LIMITEDHYDTechnology Hardware & Equipment

HYD Company Information

Name:

Hydrix Limited

Sector:

Technology

Industry:

Scientific & Technical Instruments

GIC Industry:

Electronic Equipment, Instruments & Components

GIC Sub Industry:

Electronic Equipment & Instruments

Address:

30-32 Compark Circuit Mulgrave VIC Australia 3170

Phone:

61 3 9550 8100

Full Time Employees:

75

Exec. Chairman:

Mr. Gavin Coote

Exec. VP of Corp. Devel.:

Mr. Peter R. Lewis

Financial Controller:

Mr. Mark Langham

Corp. Counsel & Company Sec.:

Ms. Alyn Tai L.L.B., LLB (Hons)

Marketing Mang.:

Mr. Alan Morris

Company Overview:

Hydrix Limited, a product design and engineering company, designs, develops, and commercializes various technologies for the medical technology, consumer and industrial products, mining, and aerospace and defense markets in Australia and internationally. The company offers a range of engineering services, including software, electronics, mechanical, industrial design, regulatory, and other services. It provides product development and commercialization services, such as applied research through various stages of engineering design, development, prototyping, manufacturer management, certification process management, and supply. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was founded in 2001 and is headquartered in Mulgrave, Australia.

HYD Share Price Information

Shares Issued:

94.60M

Market Capitalisation:

$8.14M

Revenue (TTM):

$16.33M

Revenue Per Share (TTM):

$0.24

Earnings per Share:

$-0.007

Profit Margin:

-0.1514

Operating Margin (TTM):

$-0.09

Return On Assets (TTM):

$-0.08

Return On Equity (TTM):

$-1.31

Quarterly Revenue Growth (YOY):

0.362

Gross Profit(TTM):

$11.77M

Diluted Earnings Per Share (TTM):

$-0.036

HYD CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-26,192

Change To Liabilities:

$3.29M

Total Cashflow From Investing Activities:

$-26,192

Net Borrowings:

$1.78M

Net Income:

$-4,219,742

Total Cash From Operating Activities:

$-4,197,025

Depreciation:

$199.73K

Other Cashflow From Investing Activities:

$25K

Change To Account Receivables:

$-4,673,006

Capital Expenditures:

$47.86K

HYD Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-3,994,173

Net Income:

$-4,219,742

Gross Profit:

$13.32M

Operating Income:

$-4,372,967

Other Operating Expenses:

$2.66M

Interest Expense:

$465.92K

Income Tax Expense:

$225.57K

Total Revenue:

$13.32M

Total Operating Expenses:

$17.69M

Cost Of Revenue:

$2.38M

HYD Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$2.73M

Total Liabilities:

$11.68M

Total Stockholder Equity:

$1.14M

Other Current Liabilities:

$3.09M

Total Assets:

$12.81M

Common Stock:

$79.28M

Other Current Assets:

$851.52K

Retained Earnings:

$-78,950,429

Other Liabilities:

$1.60M

Good Will:

$1.27M

Other Assets:

$766.47K

Cash:

$234.63K

Total Current Liabilities:

$10.07M

Short-Term Debt:

$4.23M

Property - Plant & Equipment:

$594.14K

Net Tangible Assets:

$-2,859,615

Long-Term Investments:

$818.49K

Total Current Assets:

$7.06M

Net Receivables:

$5.85M

Short-Term Investments:

$5.76M

Accounts Payable:

$763.61K

Non Currrent Assets (Other):

$567

Short-Term Investments:

$5.76

Non Current Liabilities Total:

$1.60M

HYD Share Price History

HYD News

29 Oct, 2019
If you're interested in Hydrix Limited (ASX:HYD), then you might want to consider its beta (a measure of share price...
02 Oct, 2019
MELBOURNE, Australia, Oct. 3, 2019 /PRNewswire/ -- Hydrix Limited (HYD.AX) ('Hydrix') has announced that it has secured the exclusive rights to distribute the AngelMed Guardian® System (Guardian) in Australia and a number of significant Asian countries including Singapore and Japan. The Guardian is the world's first FDA-approved, implanted cardiac monitoring device that can alert patients of an impending Acute Coronary Syndrome (ACS) event, which includes heart attacks and unstable angina. The faster a heart attack is diagnosed and treated, the greater the chance of a full recovery by the patient.
24 Sep, 2019
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
08 Aug, 2019
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...